R&D organizations need to offer more than an array of integrated offerings to improve human health
The Life Sciences industry is currently faced with an overwhelming array of challenges, which are requiring biopharmaceutical outsourcing providers to rethink both what and how they offer services. With the continued declines in R&D budgets and productivity as well as increasing regulatory hurdles including burden of proof outcome-based clinical trials, there is a need for new approaches and business models.
The industry is decreasing internal efforts and looking externally for innovation as well as flexible access to resources. At the same time, they are looking for fewer not more vendors for resourcing as well as ways to more efficiently manage this work in a real time period.
External providers must change not just what and how the offer services but where they offer these services. We are seeing also a shift from activity based outsourcing to sourcing of programs. This means working with partners who value, understand and protect intellectual property for their customers, and have the real-world experience and expertise to move beyond activity based sourcing.
You can register now for AMRI's webinar 'Key Considerations When Choosing a Partner for Discovery R&D' taking place on the 20th April at 10 a.m. New York/3 p.m. London.
Presented by
Michael A. Luther, Ph.D., MBA,
Senior Vice President of Discovery and Development
Michael Luther, Ph.D., leads AMRI's global discovery and development division, which provides discovery and development services to the biopharmaceutical industry, with locations in the U.S., Singapore, UK and India. Dr. Luther also is overseeing AMRI's expansion into Western New York via the development of the Buffalo Innovation Hub at Buffalo Niagara Medical Campus (BNMC Hub), a new public-private pharmaceutical research and development initiative in Buffalo, N.Y. announced by New York Governor Andrew M. Cuomo in December 2012. Before AMRI, Dr. Luther was the Corporate Vice President of Global Discovery Research Services at Charles River Laboratories, where he served as the general manager of the firm's discovery business unit, including developing and implementing strategic and operating plans. Dr. Luther also served in various leadership roles at the David H. Murdock Research Institute (DHMRI), Merck Frosst and GlaxoSmithKline.
Dr. Luther earned his Ph.D. in biochemistry from the St. Louis University School of Medicine; an M.B.A. from Duke University, Fuqua School of Business; and a B.Sc. in biological chemistry from North Carolina State University. Dr. Luther has authored numerous scientific papers and serves on Boards of Directors for a number of public and private organizations including Transgenomic, Inc., Islet Sciences, the Chagas Disease Foundation, and the College of Life Sciences Research Foundation at North Carolina State University.
